Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Rheumatol ; 2020 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-31950440

RESUMO

The first name of the co-author of the above article was presented incorrect in the published version. The author name "Miangliang Qiu" should read "Mingliang Qiu" as mentioned above.

2.
Clin Rheumatol ; 2019 Dec 26.
Artigo em Inglês | MEDLINE | ID: mdl-31879859

RESUMO

OBJECTIVE: miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs). METHOD: The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3' UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3'-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection. RESULTS: miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels. CONCLUSIONS: Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA.Key Points• SOCS1 is a potential target of miR-150-5p.• miR-150-5p promoted the growth of RASF cell line MH7A.• miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.

3.
Clin Rheumatol ; 38(8): 2053-2061, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30924010

RESUMO

OBJECTIVES: Rheumatoid arthritis (RA) may increase the risk of anxiety, but results from prior studies have no consensus. Our study aimed to evaluate the relationship between RA and incident anxiety by using a quantitative meta-analysis. METHODS: A number of databases were used to gather relevant information; they included PubMed, EMBASE, and Web of Science, with the publication date of articles limited up to July 23, 2018. To evaluate their association, an odds ratio (OR) with 95% confidence interval (CI) was used. The random-effects model played a crucial role in calculating the pooled odds ratio, while subgroup analyses and sensitivity analyses were also performed. RESULTS: A total of 10 studies, including 6201 cases of anxiety and 139,875 participants, met our inclusion criteria for this meta-analysis. All individuals were without anxiety at baseline. The follow-up period ranged from 1.0 to 9.2 years. Overall, the quantitative meta-analysis suggested that subjects with RA were associated with a significantly increased risk of anxiety incidence (OR, 1.20; 95% CI, 1.03-1.39) than those without. CONCLUSION: Results of this meta-analysis indicate that individuals with RA may confer an increased risk for the development of anxiety. Future studies should explore whether clinical manifestations of RA are modifiable risk factors for anxiety.

4.
J Clin Lab Anal ; 33(1): e22633, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30129188

RESUMO

BACKGROUND: Systemic lupus erythematosus is prone to recurrent attacks, and its treatment is related to disease activities. It is important to accurately assess the patient's disease activity. So, the purpose of this study was to investigate the relation between neutrophil-to-C3 ratio (NC3 R), neutrophil-to-lymphocyte ratio (NLR), and disease activity in patients with Systemic lupus erythematosus (SLE). METHODS: This was a retrospective study. One hundred and ninety-four patients with SLE and 71 healthy controls were included in this study. We divided the patients into two groups according to the SLE disease activity (SLEDAI). Group 1 included patients with a score of >9 (patients with severe disease activity), and Group 2 included patients with a score of 9 and lower (patients with mild disease activity). Correlations between NC3 R, NLR, and disease activity were analyzed. RESULTS: NC3 R and NLR in patients with SLE were obviously higher compared to healthy controls (P < 0.05). There was an obviously significant difference in NC3 R and NLR between Group 1 and Group 2 (P < 0.05). SLEDAI scores were positively correlated with NC3 R (r = 0.353, P < 0.01) and NLR (r = 0.237, P = 0.01). Receiver operating characteristic (ROC) curve analysis showed that the cutoff value of NC3 R to identify SLE with high disease activity was 5.935, with sensitivity and specificity being 75.9% and 67.0%, while that of NLR was 2.293, with sensitivity being 68.9% and specificity being 82.8%. CONCLUSION: NC3 R and NLR are two useful inflammatory markers for evaluating disease activity in patients with SLE.


Assuntos
Complemento C3/análise , Lúpus Eritematoso Sistêmico , Neutrófilos/citologia , Adulto , Feminino , Humanos , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/epidemiologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Masculino , Pessoa de Meia-Idade
5.
Clin Exp Rheumatol ; 36(5): 836-840, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29600939

RESUMO

OBJECTIVES: To introduce the Chinese Registry of rhEumatoiD arthrITis (CREDIT), which is the first nationwide, multicentre, online rheumatoid arthritis (RA) registry in China, and to depict major cross-sectional data and treatment strategies of Chinese RA patients. METHODS: RA patients who fulfilled the 2010 ACR/EULAR classification criteria for rheumatoid arthritis were recruited into the registry by their rheumatologists from 144 clinical centres in China. Data, including demographics, disease characteristics, co-morbidities, treatment, and adverse reactions, were collected and documented through the predefined protocol. RESULTS: 8071 registered patients (F:M = 4.03:1) were registered up to May 2017. Mean age at symptom onset and at diagnosis was 46.15±14.72y and 48.68±14.54y, respectively. Point prevalence of remission (95% CIs) was 14.88% (14.10-15.66%), 4.23% (3.79-4.66%), 4.25% (3.81-4.69%), and 4.27% (3.83-4.72%) according to DAS28-CRP, CDAI, SDAI, and the 2011 ACR/EULAR remission criteria, respectively. 38.84% and 38.11% of treatment-naïve patients (n=3262) were in moderate (3.25.1) disease activity, respectively. Among treatment-naïve patients, those who were initiated on treatment with bDMARDs had higher disease activity than those who were treated with csDMARDs (p<0.05). Three months after initiating bDMARDs, 19.29% (n=38) of patients achieved remission (DAS28-CRP<2.6). CONCLUSIONS: The CREDIT registry is an effective tool for real-world study of RA patients in China. By providing information for diagnosis and treatment regimen, the CREDIT registry can enhance the application of treat-to-target (T2T) strategy and improve patient outcomes in China.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Sistema de Registros , Adulto , Idoso , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/epidemiologia , China/epidemiologia , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Padrões de Prática Médica/tendências , Prevalência , Indução de Remissão , Fatores de Tempo , Resultado do Tratamento
6.
Arthritis Res Ther ; 19(1): 251, 2017 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-29141688

RESUMO

BACKGROUND: Rheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities. METHODS: Baseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses. RESULTS: A total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0-2.5%); fragility fracture, 1.7% (95% CI 1.5-1.9%); malignancy, 0.6% (95% CI 0.5-0.7%); overall major comorbidities, 4.2% (95% CI 3.9-4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities. CONCLUSIONS: Patients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.


Assuntos
Artrite Reumatoide/epidemiologia , Doenças Cardiovasculares/epidemiologia , Fraturas Ósseas/epidemiologia , Neoplasias/epidemiologia , Sistema de Registros/estatística & dados numéricos , Adulto , Idoso , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/etnologia , Grupo com Ancestrais do Continente Asiático , Doenças Cardiovasculares/etnologia , China , Comorbidade , Feminino , Fraturas Ósseas/etnologia , Humanos , Modelos Logísticos , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Neoplasias/etnologia , Prevalência , Fatores de Risco
7.
Mil Med Res ; 4: 14, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28465831

RESUMO

The gut microbiota, the largest symbiotic ecosystem with the host, has been shown to play important roles in maintaining intestinal homeostasis. Dysbiosis of the gut microbiome is caused by the imbalance between the commensal and pathogenic microbiomes. The commensal microbiome regulates the maturation of the mucosal immune system, while the pathogenic microbiome causes immunity dysfunction, resulting in disease development. The gut mucosal immune system, which consists of lymph nodes, lamina propria and epithelial cells, constitutes a protective barrier for the integrity of the intestinal tract. The composition of the gut microbiota is under the surveillance of the normal mucosal immune system. Inflammation, which is caused by abnormal immune responses, influences the balance of the gut microbiome, resulting in intestinal diseases. In this review, we briefly outlined the interaction between the gut microbiota and the immune system and provided a reference for future studies.


Assuntos
Microbioma Gastrointestinal/fisiologia , Imunidade nas Mucosas/fisiologia , Interações Microbianas/fisiologia , Humanos , Imunidade Inata/imunologia , Imunidade Inata/fisiologia , Intestinos/imunologia
8.
Clin Rheumatol ; 34(9): 1513-9, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26139202

RESUMO

This study aimed to investigate the efficacy and safety of iguratimod (T-614) in combination with methotrexate (MTX) for active rheumatoid arthritis (RA) patients. Sixty active RA patients were enrolled according to the 2010 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria, and were randomized into MTX + T-614 group and MTX group. T-614 was orally administered at a dosage of 50 mg/day (25 mg twice daily) for 24 weeks. MTX was orally administered to RA patients at a stable weekly dosage of 10 mg/week for the first 4 weeks and subsequent 12.5 mg/week for the later 20 weeks. Clinical features at baseline and efficacy endpoints of the ACR 20 % response (ACR20), ACR50, ACR70, and adverse events at 24 weeks were evaluated, respectively. After 24 weeks of treatment, clinical features at baseline, including counts for tender joints and swelling joints, visual analog scale for pain, patient's and physician's global assessment, erythrocyte sedimentation rate, C-reactive protein, disease activity score 28, health assessment questionnaire, simplified disease activity index, and ACR50 in the MTX + T-614 group, showed statistically significant differences comparing with the MTX group (P < 0.05). There was no significant increase in adverse events in the MTX + T-614 group comparing with the MTX group (P > 0.05). The combination of MTX and T-614 therapy appeared to have a good efficacy and safety for active RA and was superior to MTX-alone therapy after 24 weeks of treatment.


Assuntos
Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Proteína C-Reativa/análise , Cromonas/administração & dosagem , Metotrexato/administração & dosagem , Sulfonamidas/administração & dosagem , Adulto , Antirreumáticos/efeitos adversos , China , Cromonas/efeitos adversos , Quimioterapia Combinada , Feminino , Humanos , Masculino , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Sulfonamidas/efeitos adversos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA